Diagnostic and management strategies for diffuse interstitial lung disease

Chest

Volumn 113, Issue 1, 1998, Pages 192-202

  Reynolds, Herbert Y ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; STEROID;

ALGORITHM; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG TRANSPLANTATION; PATIENT MONITORING; PATIENT SATISFACTION; PRIORITY JOURNAL; REVIEW; THORACOSCOPY; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0031963470     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.113.1.192     Document Type: Review

References (90)

1. Rankin JA, Naegel GP, Schrader CK, et al. Airspace immunoglobulin production and levels in bronchoalveolar lavage fluid of normals and patients with sarcoidosis. Am Rev Respir Dis 1983; 127:442-48
2. Sandron D, Reynolds HY, Venet A, et al. Human alveolar macrophage subpopulations isolated on discontinuons albumin gradients: functional data in normals and sarcoid patients. Eur J Respir Dis 1986; 69:226-34
3. Rankin JA, Kaliner M, Reynolds HY, Histamine levels in bronchoalveolar lavage from patients with asthma, sarcoidosis and idiopathic pulmonary fibrosis. J Allergy Clin Immunol 1987; 79:371-77
4. Stoller JK, Rankin JA, Reynolds HY. The impact of bronchoalveolar lavage cell analysis on clinicians diagnostic reasoning about interstitial lung disease. Chest 1987; 92:839-43
5. Rankin JA, Huang SS, Sostman HD, et al. An analysis of the inter-relationships among multiple bronchoalveolar lavage and serum determinations, physiologic tests, and clinical disease activity in patients with sarcoidosis. Sareoidosis 1991; 8:19-28
6. Crystal RJ, Fulmer JD, Roberts WC, et al. Idiopathic pulmonary fibrosis: clinical, histologic, radiographic, physiologic, scintigraphic, cytologic and biochemical aspects. Ann Intern Med 1976; 85:769-88
7. Reynolds HY, Fulmer JD, Kazmicrowski JA, et al. Analysis of cellular and protein components of bronchoalveolar lavage fluid from patients with idiopathic pulmonary fibrosis and hypersensitivity pneumonitis. J Clin Invest 1977; 59:165-75
8. Weinlierger SE, Kelman JA, Elson NA, et al. Bronchoalveolar lavage in interstitial lung disease. Ann Intern Med 1978; 89:459-66
9. Gadek J, Kelman J, Weinberger S, et al. Connective tissue specific enzymes of bronchoalveolar fluids in idiopathic pulmonary fibrosis. N Engl J Med 1979; 301:737-42
10. Marcy T, Reynolds HY. Pulmonary histiocytosis X. Lung 1985; 163:129-50
11. Reynolds HY. Hypersensitivity pneumonitis. In: Fulmer JD, ed. Clinics in chest medicine (vol 3). Philadelphia: WB Saunders, 1982; 503-19
12. Reynolds HY, Chrétien J. Respiratory tract fluids: analysis of content and contemporary use in understanding lung diseases. Dis Mon 1984; 30:1-103
13. Reynolds HY. Bronchoalveolar lavage - state of the art. Am Rev Respir Dis 1987; 135:250-63
14. Reynolds HY, Pulmonary sarcoidosis: do cellular and immunochemical lung parameters exist that would separate subgroups of patients for prognosis? Sarcoidosis 1989; 6:1-4
15. Reynolds HY. Immunologic concepts relating to the pathogenesis of diffuse interstitial lung diseases. Trans Am Clin Climatol Assoc 1980; 91:16-31
16. du Bois RM. Diffuse lung disease: an approach to management. BMJ 1994; 309:175-79
17. Raghu G. Interstitial lung disease: a diagnostic approach. Am J Respir Crit Care Med 1995; 151:909-14
18. Carrington CB, Gaensler EA, Coutu RE, et al. Natural history and treated course of usual and desquamative interstitial pneumonia. N Engl J Med 1978; 298:801-9
19. Crystal RC, Bitterman PB, Rennard SI, et al. Interstitial lung diseases of unknown cause: disorders characterized by chronic inflammation of the lower respiratory tract (first of two parts). N Engl J Med 1984; 310:154-66
20. Liebow AA, Steer A, Billingsley JC. Desquamative interstitial pneumonia. Am J Med 1965; 38:369-404
21. Scadding JC, Hinson KFW. Diffuse fibrosing alveolitis (diffuse interstitial fibrosis of the lungs) - correlation of histology at biopsy with prognosis. Thorax 1967; 22:291-304
22. Fishman AP. UIP, DIP and all that [editorial]. N Engl J Med 1978; 298:843-45
23. Turner-Warwick M, Burrows B, Johnson A. Cryptogenic fibrosing alveolitis: clinical features and their influence on survival. Thorax 1980; 35:171-80
24. Schuyler M, Cormier Y. The diagnosis of hypersensitivity pneumonitis. Chest 1997; 111:534-36
25. Tonnel AB, Lahoute C, Lebas J, et al. Cellular and biochemical features of bronchoalveolar lavages in bird fancier's lung: correlation with provocation tests: bronchoalveolar lavage in man. INSERM 1979; 84:329-35
26. Reynolds HY. Hypersensitivity pneumonitis: correlation of cellular and immunologic changes with clinical phases of disease-review. Lung 1991; 169:S109-28
27. Trentin L, Migone N, Zambello H, et al. Mechanisms accounting for lymphocytic alveolitis in hypersensitivity pneumonitis. J Immunol 1990; 145:2147-54
28. Cormier Y, Laviolette M, Cantin A, et al. Fibrogenic activities in bronchoalveolar lavage fluid of farmer's lung. Chest 1993; 104:1038-42
29. Cooper JAD Jr, Matthay RA. Drug-induced pulmonary disease. Dis Mon 1987; 33:66-120
30. Rosenow EC III, Myers JL, Swenson SJ, et al. Drug-induced pulmonary disease: an update. Chest 1992; 102:239-50
31. Winterbauer RH, Wilske KR, Wheelis RF. Diffuse pulmonary injury associated with gold treatment. N Engl J Med 1976; 294:919-21
32. Leduc D, De Vuyst P, Lheureux P, et al. Pneumonitis complicating low-dose methotrexate therapy for rheumatoid arthritis: discrepancies between lung biopsy and bronchoalveolar lavage findings. Chest 1993; 104:1620-23
33. McEwan SR, Clark RA, Guthrie W. Dothiepin and fatal fibrosing alveolitis [letter]. Lancet 1986; 1:970
34. Veale D, Gilmartin JJ. Acute alveolitis associated with dothiepin treatment. BMJ 1985; 290:606
35. Panuska JR, King TR, Korenblat PE. Hypersensitivity reaction to desipramine. J Allergy Clin Immunol 1987; 80:18-23
36. Kahrilas PJ. Gastroesophageal reflux disease. JAMA 1996; 276:983-88
37. Hunninghake GW, Fauci AS. Pulmonary involvement in the collagen vascular diseases. Am Rev Respir Dis 1979; 119:471-503
38. Helmers R, Galvin J, Hunninghake GW. Pulmonary manifestations associated with rheumatoid arthritis. Chest 1991; 100:235-38
39. McDonagh J, Greaves M, Wright AR, et al. High resolution computed tomography of the lungs in patients with rheumatoid arthritis and interstitial lung disease. Br J Rheumatol 1994; 33:118-22
40. Baughman RP. Sarcoidosis - usual and unusual manifestations. Chest 1988; 94:165-70
41. DeRemee RA. Sarcoidosis - concise review for primary care physicians. Mayo Clin Proc 1995; 70:177-81
42. Muller NL, Miller RR. Computed tomography of chronic diffuse infiltrative lung disease, part I and II. Am Rev Respir Dis 1990; 142:1206-15, 1440-48
43. Wheeler JH, Fishman EK. Computed tomography in the management of chest infections: current status. Clin Infect Dis 1996; 23:232-40
44. Epler GR, McLoud TC, Gaensler EA, et al. Normal chest roentgenograms in chronic diffuse infiltrative lung disease. N Engl J Med 1978; 298:934-39
45. Orens JB, Kazerooni EA, Martinez FJ, et al. The sensitivity of high-resolution CT in detecting idiopathic pulmonary fibrosis proved by open lung biopsy: a prospective study. Chest 1995; 108:109-15
46. Nishimiira K, Izumi T, Kitaichi M, et al. The diagnostic accuracy of high-resolution computed tomography in diffuse infiltrative lung diseases. Chest 1993; 104:1149-55
47. Primack SL, Hartman TE, Hansell DM, et al. End-stage lung disease: CT findings in 61 patients. Radiology 1993; 189: 681-86
48. Remy-Jardin M, Girand F, Remy J, et al. Importance of ground-glass attenuation in chronic diffuse infiltrative lung disease: pathologic-CT correlation. Radiology 1993; 189:693-98
49. Wells AU, Hansell DM, Rubens MB, et al. The predictive value of appearances of thin section computed tomography in fibrosing alveolitis. Am Rev Respir Dis 1993; 148:1076-82
50. Gaensler KA, Carrington CB. Open biopsy for chronic diffuse infiltrative lung disease: clinical, roentgenographic and physiologic correlation in 502 patients. Ann Thorac Surg 1980; 30:411-26
51. Levin DC, Wicks AB, Ellis JH Jr. Transbronchial lung biopsy via the fiberoptic bronchoscope. Am Rev Respir Dis 1974; 110:4-12
52. Credle WF Jr, Smiddy JF, Elliott RC. Complications of fiberoptic bronchoscopy. Am Rev Respir Dis 1974; 109:67-72
53. Fulkerson WJ. Fiberoptic bronchoscopy - current concepts. N Engl J Med 1984; 311:511-15
54. Koontz CH. Lung biopsy in sarcoidosis. Chest 1978; 74: 120-21
55. Bensard DD, McIntyre RC Jr, Waring BJ, et al. Comparison of video thoracoscopic lung biopsy to open lung biopsy in the diagnosis of interstitial lung disease. Chest 1993; 103:765-70
56. Jaklitsch MT, DeCamp MM Jr, Liptay MJ, et al. Video-assisted thoracic surgery in the elderly: a review of 307 cases. Chest 1996; 110:751-58
57. Strumpf IJ, Feld MK, Cornelius MJ, et al. Safety of fiberoptic bronchoaiveolar lavage in evaluation of interstitial lung disease. Chest 1981; 80:268-71
58. Semenzato G, Chilosi M, Ossi E, et al. Bronchoalveolar lavage and lung histology: comparative analysis of inflammatory and immunocompetent cells in patients with sarcoidosis and hypersensitivity pneumonitis. Am Rev Respir Dis 1985; 132:400-4
59. Hunninghake GW, Gadek JE, Kawanami O, et al. Inflammation and immune processes in the human lung in health and disease: evaluation by bronchoalveolar lavage. Am J Pathol 1979; 97:149-206
60. Daniele RP, Elias JA, Epstein PE, et al. Bronchoalveolar lavage: role in pathogenesis, diagnosis and management of interstitial lung disease. Ann Intern Med 1985; 102:93-108
61. Turner-Warwick ME, Haslam PL. Clinical applications of bronchoalveolar lavage: an interim view. Br J Dis Chest 1986; 80:105-21
62. Goldstein RA, Rohatgi PK, Bergofsky EH, et al. Clinical role of bronchoalveolar lavage in adults with pulmonary disease. Am Rev Respir Dis 1990; 142:481-86
63. Drent M, van Nierop MAMF, Gerritsen FA, et al. A computer program using BALF-analysis results as a diagnostic tool in interstitial lung diseases. Am J Respir Crit Care Med 1996; 153:736-41
64. Behr J, Vogelmeier C, Beinert T, et al. Bronchoalveolar lavage for evaluation and management of scleroderma disease of the lung. Am J Respir Crit Care Med 1996; 154:400-06
65. Mapel DW, Sainct JM, Conllas DB. Corticosteroids and the treatment of idiopathic pulmonary fibrosis: past, present and future. Chest 1996; 110:1058-67
66. Lynch JP, McCune WJ. Immunosuppressive and cytotoxic pharmacology for pulmonary disorders. Am J Respir Crit Care Med 1997; 155:395-420
67. Reynolds HY, Idiopathic pulmonary fibrosis. In: Lichtenstein LM, Fanci AS, eds. Current therapy in allergy, immunology and rheumatology (vol 3). New York: BC Decker, 1988; 214-20
68. Dayton CS, Schwarz DA, Helmers RA, et al. Outcome of subjects with idiopathic pulmonary fibrosis who fail corticosteroid therapy: implications for further study. Chest 1993; 103:69-73
69. Raglm G, DePaso WJ, Cain K, et al. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective, double-blind, randomized, placebo-controlled clinical trial. Am Rev Respir Dis 1991; 144:291-96
70. Baughman RP, Lower EE. Use of intermittent, intravenous cyclophosphamide for idiopathic pulmonary fibrosis. Chest 1992; 102:1090-94
71. Johnson MA, Kwan S, Snell JC, et al. Randomized controlled trial comparing prednisone alone with cyclosphosphamide and low dose prednisone in combination in cryptogenic fibrosing alveolitis. Thorax 1989; 44:280-88
72. O'Donnell K, Keogh B, Cantin A, et al. Pharmacologie suppression of the neutrophil component of the alveolitis in idiopathic pulmonary fibrosis. Am Rev Respir Dis 1987; 136:288-92
73. Violi L, Pacht E. Low dose cyclophosphamide as a first line therapy for IPF [abstract]. Am J Respir Crit Care Med 1997; 155:A322
74. Trulock EP. Lung transplantation: state of the art. Am J Respir Crit Care 1997; 155:789-818
75. Peters SG, McDougall JC, Douglas WW, et al. Colchicine in the treatment of pulmonary fibrosis. Chest 1993; 103:101-04
76. Rennard SI, Bitterman PG, Ozaki T, et al. Colchicine suppresses the release of fibroblast growth factors from alveolar macrophages in vitro: the basis of a possible therapeutic approach to the fibrotic disorders. Am Rev Respir Dis 1988: 137:181-85
77. Entizian P, Schlaak M, Seitzer U, et al. Anti-inflammatory and antifibrotic properties of colchicine: implications for idiopathic pulmonary fibrosis. Lung 1997; 175:41-51
78. Hunninghake GW, Kalica AR. Approaches to the treatment of pulmonary fibrosis. Am J Respir Crit Care Med 1995; 151:915-18
79. Douglas WW, Ryu JH, Bjoraker JA, et al. Colchicine therapy for idiopathic pulmonary fibrosis [abstract]. Am Rev Respir Crit Care Med 1996; 153:A149
80. Douglas WW, Ryu JH, Bjoraker JA, et al. Colchicine versus prednisone as treatment of usual interstitial pneumonia. Mayo Clin Proc 1997; 72:201-09
81. Douglas WW, Ryu JH, Swensen SJ, et al. Colchicine versus prednisone in the treatment of usual interstitial pneumonitis: a randomized prospective study [abstract]. Am J Respir Crit Care Med 1997; 155:A741
82. Addrizzo-Harris DJ, Harkin TJ, Naidich DP, et al. Clinical trial of colchicine in pulmonary fibrosis [abstract]. Am J Respir Crit Care Med 1996; 153:A149
83. Christopher KL, Spofford BT, Petrun MD, et al. A program for transtracheal oxygen delivery. Ann Intern Med 1987; 107:802-08
84. Trochtenberg S. Nebulized lidocaine in the treatment of refractory cough. Chest 1994; 105:1592-93
85. Almansa-Pastor A. Treating refractory cough with aerosols of mepivacaine [letter]. Chest 1996; 110:1374-75
86. Line BR, Fulmer JD, Reynolds HY, et al. Gallium 67 citrate scanning in the staging of idiopathic pulmonary fibrosis: correlation with physiologic and morphologic feature and bronchoalveolar lavage. Am Rev Respir Dis 1978; 118:355-65
87. Hanson D, Winterbauer RH, Kirtland SH, et al. Changes in pulmonary function test results after 1 year of therapy as predictors of survival in patients with idiopathic pulmonary fibrosis. Chest 1995; 108:305-10
88. Erbes R, Schaberg T, Loddenkemper R. Lung function tests in patients with idiopathic pulmonary fibrosis: are they helpful for predicting outcome? Chest 1997; 111:51-57
89. Kirtland SH, Winterbaner RH. Pulmonary function tests and idiopathic pulmonary fibrosis: simple may be better [editorial]. Chest 1997; 111:7-8
90. Hartman TE, Primack SL, Kang E-Y, et al. Disease progression in usual interstitial pneumonia compared with desquamative interstitial pneumonia: assessment with serial CT. Chest 1996; 110:378-82